Buzzmakers: Prince Michael Reports for ET and Mindy McCready Dies

What had ETOnline readers buzzing this week?

1. Prince Michael Jackson is New ET Correspondent

Having grown up in show business, Prince Michael proved to be a gifted interviewer as he conducted his first sit-down as an ET correspondent.

Michael Jackson's 16-year-old son impressed Oz the Great and Powerful stars James Franco and Zach Braff as well as director Sam Raimi with his confidence and competence on his first assignment.

"You're doing awesome," Braff gushed. "You're a natural."

Prince Michael returned the compliment, praising their work in the fantasy flick and getting Franco to shed some light on how he approached playing the lead role of Oscar Diggs, a small-time circus magician with dubious ethics.

"I saw that his particular transformation would allow for comedy," Franco explained. "Because he's a conman -- that would get him into a lot of awkward situations that could be played for comedy."

The movie imagines the origins of L. Frank Baum's beloved character from The Wizard of Oz. After Oscar Diggs (Franco) is hurled away from dusty Kansas to the vibrant Land of Oz, he first thinks he's hit the jackpot -- until he meets three witches, Theodora (Mila Kunis), Evanora (Rachel Weisz) and Glinda (Michelle Williams), who are not convinced he is the great wizard everyone's been expecting.

2. Country Music Stars Mourn Mindy McCready's Death

The country music community is mourning the loss of one of their own. Country crooner Mindy McCready was found dead of apparent suicide on Sunday, Feb. 17, at her Arkansas home. She was 37. Needless to say, this has caused an outpouring of sympathetic tweets from McCready's musician peers.

Here are some of the stars' reactions to the tragic news:

LeAnn Rimes: "Mindy and I both started our careers around the same time. We worked with a lot of the same people, so we ended up spending lots of time around one another. She was always so kind and very protective of me, like a big sis. My heart is broken that she's gone."

Carrie Underwood: "I grew up listening to Mindy McCready...so sad for her family tonight. Many prayers are going out to them..."

Clay Aiken: "I listened admiringly to Mindy McCready growing up. May she finally be at peace and lend her beautiful voice to heaven's."

Lady Antebellum's Hillary Scott: "My heart is breaking hearing of the loss of Mindy McCready. Pray for her 2 precious little boys...may God's peace & protection be on them!"

Jason Aldean: "Just heard about Mindy McCready. My thoughts and prayers are with her 2 boys and her family."

Big and Rich's John Rich: "Very sad to hear about Mindy McCready. When I was in Lonestar she was our label mate and we were friends. A tragic end to a talented life."

Wynona Judd: "Oh my! Mindy. Dear sweet girl. This is so sad. It just breaks my heart what addiction continues to take from this life. Addiction is a dis EASE and not a character flaw. When the pain becomes too much, it causes people to want that pain to stop. This is just so Unbelievable and so sad. God be with the family and those babies. Surround them with your grace & mercy. Sleep in Heavenly peace Mindy."

Martina McBride: "So sad."

Chely Wright: "Really really sad to learn the news about Mindy McCready. I will pray for her children and I hope that people are gentle with her memory."

Gretchen Peters: "So sad to hear about Mindy McCready. I met her in the first flush of her early career. This is a hard business. Sometimes success is poison."

3. Mark Hamill Reveals He's in Talks to Appear in New 'Star Wars'

Mark Hamill's new movie Sushi Girl hits DVD and Blu-ray this week, and while talking about the project, the Star Wars legend was more than happy to provide ETonline with an update on his involvement with the in-development Star Wars VII – and what he thinks of those planned spinoff movies…

"It's all very, very exciting and so unexpected," says Hamill. "I think that's the quality I like about it most – it's like getting a pair of pants out of the closet you haven't worn in three years and finding a $20 bill in the pocket. It's just so unexpected."

First off, will he appear in Star Wars VII? "They're talking to us," he reveals. "George [Lucas] wanted to know whether we'd be interested. He did say that if we didn't want to do it, they wouldn't cast another actor in our parts – they would write us out. … I can tell you right away that we haven't signed any contracts. We're in the stage where they want us to go in and meet with Michael Arndt, who is the writer, and Kathleen Kennedy, who is going to run Lucasfilm. Both have had meetings set that were postponed -- on their end, not mine. They're more busy than I am."

Hamill, 61, says he's intrigued about where the new trilogy could go but says he knows nothing about the storyline: "I probably learn more from Entertainment Tonight than I do directly from Lucasfilm – like for instance, when George told us he wanted to do the next trilogy, he didn't tell us it was going to be done for Disney. He saved that little nugget, and I read it online like anybody else."

As for his thoughts about the next trilogy's tone, "I said to George that I wanted to go back to the way it was, in the sense that ours was much more carefree and lighthearted and humorous – in my opinion, anyway. And another thing I'd want to make sure of is are we going to have the whole gang back? Is Carrie and Harrison and Billy Dee and Tony Daniels, everybody that's around from the original [returning]? I want to make sure that everybody's on board here, rather than just one. I guess I'll have to tune into your show to figure out who's on board."

In terms of where we'll pick up with Luke Skywalker in Star Wars VII, "I'm assuming, because I haven't talked to the writers, that these movies would be about our offspring -- like my character would be sort of in the Obi-Wan range [as] an influential character. … When I found out [while making the original trilogy] that ultimate good news/bad news joke – the good news is there's a real attractive, hot girl in the universe; the bad news is she's your sister – I thought, 'Well, I'm going to wind up like Sir Alec [Guinness]. I'm going to be a lonely old hermit living out in some kind of desert igloo with a couple of robots.'"

Hamill concludes of the next movie, "I hope they find the right balance of CGI with practical effects. I love props, I love models, miniatures, matte paintings -- I'm sort of old school. I think if you go too far in the direction of CGI it winds up looking like just a giant a video game, and that's unfortunate. … If they listen to me at all, it'll be, 'Lighten up and go retro with the way it looks.'"

As for those confirmed stand-alone Star Wars films, which may follow the adventures of a young Han Solo, Boba Fett and Yoda, Hamill observes, "That's really smart. Then you're more like James Bond pictures, where they come out and it's not an investment of a three-movie arc. … It's so rich, that [Star Wars] universe, in terms of quirkiness and oddball [nature]. We would talk about that [on the original film's set]. We'd go like, 'That little band that's playing in the Cantina, what's their story?! I mean, are they a traveling band? Are they the house band? Who's their manager?' They didn't have names when we first were talking about them. Now they're called, like, Sy Snootles – they come up with names down the road when they have to name toys."

So what spinoff movie would Mark Hamill like to see? "Oh, I don't know, set it on the Wookiee planet -- although that might be prohibitively expensive with that many Wookiees," he says with some resignation. After a little more thought, he muses, "That's what I would love. You pick the most insignificant little [character] – there's this little hawk-beaked character that's somewhere in Jabba's palace, I can't even remember what function he served -- but that's what I would think. You pick something that almost nobody remembers or knows about -- and then have a movie about him! You could probably put about 500 different character's names on a big, giant dart board, throw a dart, and say, 'Okay, wherever it lands we've got to make him the central character.'"
After a hearty laugh, Hamill adds, "I hope we don't overstay our welcome."

4. Nina Dobrev Reflects on Shocking 'Vampire Diaries' Death

Death has loomed large over Elena Gilbert since The Vampire Diaries pilot, but absolutely nothing will compare with the pain she's forced to endure now that her brother, Jeremy, has fallen victim to vampires.

The shocking death not only devastated fans, but the actors -- Steven McQueen included -- as well. And anyone assuming TVD finds a way to make the best of a bad situation is wrong. Dead wrong. According to Nina Dobrev things are about to get real dark for Elena, whose grief will make her unrecognizable to fans in the coming weeks.

ETonline: This season has been a thrill from the start. What's your feeling about season four?

Nina Dobrev: It's been really cool, especially because you always hear actors say doing a TV show for X amount of years can be boring and repetitive, but over the last four years, Elena has been changing and evolving and growing so much. Julie [Plec, executive producer] has done such an incredible job of keeping it fresh and exciting and making me excited to come to work every day. Especially this season -- and especially with the death of Jeremy. Between last week's episode and this week's, it's been very challenging for me as an actress, but very fulfilling. It's an emotional rollercoaster and I had to go to some dark places.

ETonline: What was your reaction to finding out Jeremy would be killed?

Dobrev: I think we were all shocked and surprised, but that's the show -- it's a vampire show, people have to die all the time. And for Elena, it was very important that she lose Jeremy for what she's about to go through. It becomes a big part of her journey. I know Steven was very bummed, but also excited because he had a lot to do leading up to it -- his character grew and became so strong. It's bittersweet but made for some amazing television.

ETonline: In many ways, Jeremy was the person who really kept Elena tethered to her humanity. Will this loss threaten to make Elena embrace the less desirable sides of vampirism?

Dobrev: Jeremy was the last person she had left, so it's very likely that Elena could go off the deep end now that she doesn't have the one thing that kept her human. Elena wants to protect the people she loves and saw this new-found strength as a way to protect everyone. But, in this case, she couldn't protect Jeremy and lost the only family member she had left. She won't take it lightly. It's going to destroy her.

ETonline: Jeremy was also one of the only remaining characters who touched everyone in Mystic Falls. Will his death, in some ways, reinforce the group?

Dobrev: They do come together, but everyone is sort of walking on pins and needles around Elena so they don't trigger something and send her into a psychotic break. They live in a mystical world, so just because Jeremy's dead, it doesn't mean he's really dead in her mind. So she's looking for any solution she can to bring him back -- Elena is basically mentally unstable, going a little crazy and everyone is trying to help.

ETonline: Obviously Elena still misses Jenna and Alaric, but I would imagine losing Jeremy has a much more profound and prolonged effect on her. True?

Dobrev: Losing Jeremy really, really, really changes Elena. Sometimes people recover from tragedy and sometimes they don't -- but it's a long journey for her. Elena's mourning peroid is much different than any I've ever seen depicted on TV before. She goes off the deep end and spirals downwards into a black hole of death and sadness and misery. I mean, your instinct is right when you asked if we'll see an Elena who embraces her vampire side to a different degree. It's an Elena we haven't seen before, and you'll be shocked, quite frankly. I was very surprised where the episodes take her because it's almost like she's a completely different person that you won't recognize to some degree.

5. Fergie Reveals: I'm Pregnant!

Congratulations are in order for Fergie and Josh Duhamel, as the couple announced this week that they're expecting their first child!

"Josh & Me & BABY makes three," she Tweeted, along with the hashtag #MyLovelyBabyBump

Fergie and Duhamel married on January 10, 2009, after five years of dating.

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.

Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.

Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.

"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.

Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.

But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.

National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.

"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.

OPTIONS BULLS TARGET GAINS

The spending cuts, if they go ahead, could hit the defense industry particularly hard.

Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.

Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.

"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.

The stock ended up 0.6 percent at $88.12 on Friday.

If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.

General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.

EYES ON GDP DATA, APPLE

The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.

U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.

Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.

Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.

On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.

(Additional reporting by Doris Frankel; Editing by Kenneth Barry)

Read More..

Abe: Japan acting calmly in island dispute with China

WASHINGTON (Reuters) - Japanese Prime Minister Shinzo Abe on Friday said he told President Barack Obama in a meeting that Japan would act calmly in its row with China over tiny islands in the East China Sea claimed by both Asian countries.

"I explained that we have always been dealing with this issue ... in a calm manner," he said through a translator, while sitting next to Obama in the White House Oval Office.

"We will continue to do so and we have always done so," he said.

Tension has raised fears of an unintended military incident near the islands, known as the Senkaku in Japan and the Diaoyu in China. Washington says the islets fall under a U.S.-Japan security pact, but it is eager to avoid a clash in the region.

Abe said the existence of the Japan-U.S. alliance was a stabilizing factor in the area.

"We agreed that we would stay in close coordination with each other in dealing with such issues and other issues," he said.

Obama, in his remarks to reporters, said Japan was one of the United States' closest allies. He said the two men would discuss trade and other economic issues and agreed that their top priority was economic growth.

Obama declined to answer a reporter's question on whether they would discuss the Japanese yen.

Expectations for Abe's economic programs, especially monetary easing, have cut some 10 percent off the yen's value against the U.S. dollar since Abe took office, raising concern that Japan is weakening its currency to export its way out of recession.

Obama and Abe also discussed North Korea and agreed to cooperate at the United Nations over the issue. Abe said the two men also talked about additional sanctions against North Korea, which tested a nuclear bomb last week in defiance of U.N. resolutions.

(Editing by Vicki Allen)

Read More..

Dwayne Johnson Talks 'Snitch'

Dwayne Johnson is forced to drive for a ruthless drug cartel in the gritty action-thriller Snitch, in theaters today, and the towering star with a heart of gold tells ET, "I would go through heaven and hell to protect my child."

Pics: They Dated?! Surprising Celebrity Hookups

"At the heart of this film it is about family, and I would do anything to protect my family," says Johnson. "It's what we do as adults – we protect our children from harm, from danger."
At the center of the film is a serious showpiece, the edge-of-your-seat big rig chase, and we asked Johnson if he was able to drive the truck himself.

Flashing his trademark grin, he replied, "You bet your ass I know how to drive that big rig. I loved driving that. The big rig became a character in and of itself in this movie."

Snitch finds Johnson as a concerned father faced with a dramatic choice after his teenage son is wrongly accused of a drug distribution crime. With his boy facing a minimum prison sentence of 10 years, the desperate and determined Johnson makes a deal with the U.S. attorney to work as an undercover informant and infiltrate a dangerous drug cartel (whose key player is played by Benjamin Bratt). Willing to risk everything to free his son, can Johnson make it out alive? Susan Sarandon, Barry Pepper and Jon Bernthal also star.

Video: Johnson Talks 'G.I. Joe: Retaliation'

Johnson adds, "Because [the movie is based on a] true story, I wanted to make sure that all of the elements are preserved and respected."

Read More..

FDA approves new targeted breast cancer drug

WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug.

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was co-developed by South San Francisco-based Genentech and ImmunoGen Inc., of Waltham, Mass. ImmunoGen developed the technology that binds the drug ingredients together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.

Shares of ImmunoGen Inc. slipped 8 cents to $14.22 in afternoon trading. They have traded in a 52-wek range of $10.85 to $18.10.

Read More..

French, Malian forces fight Islamist rebels in Gao

GAO, Mali (Reuters) - French and Malian troops fought Islamists on the streets of Gao and a car bomb exploded in Kidal on Thursday, as fighting showed little sign of abating weeks before France plans to start withdrawing some forces.

Reuters reporters in Gao in the country's desert north said French and Malian forces fired at the mayor's office with heavy machineguns after Islamists were reported to have infiltrated the Niger River town during a night of explosions and gunfire.

French Defense Minister Jean-Yves Le Drian told a news conference in Brussels that Gao was back under control after clashes earlier in the day.

"Malian troops supported by French soldiers killed five jihadists and the situation is back to normal," he said.

In Kidal, a remote far north town where the French are hunting Islamists, residents said a car bomb killed two. A French defense ministry source reported no French casualties.

French troops dispatched to root out rebels with links to al Qaeda swiftly retook northern towns last month. But they now risk being bogged down in a guerrilla conflict as they try to help Mali's weak army counter bombings and raids.

"There was an infiltration by Islamists overnight and there is shooting all over the place," Sadou Harouna Diallo, Gao's mayor, told Reuters by telephone earlier in the day, saying he was not in his office at the time.

Gao is a French hub for operations in the Kidal region, about 300 km (190 miles) northeast, where many Islamist leaders are thought to have retreated and foreign hostages may be held.

"They are black and two were disguised as women," a Malian soldier in Gao who gave his name only as Sergeant Assak told Reuters during a pause in heavy gunfire around Independence Square.

Six Malian military pickups were deployed in the square and opened fire on the mayor's office with the heavy machineguns. Two injured soldiers were taken away in an ambulance.

French troops in armored vehicles later joined the battle as it spilled out into the warren of sandy streets, where, two weeks ago, they also fought for hours against Islamists who had infiltrated the town via the nearby river.

Helicopters clattered over the mayor's office, while a nearby local government office and petrol station was on fire.

A Gao resident said he heard an explosion and then saw a Malian military vehicle on fire in a nearby street.

Paris has said it plans to start withdrawing some of its 4,000 troops from Mali next month. But rebels have fought back against Mali's weak and divided army, and African forces due to take over the French role are not yet in place.

Islamists abandoned the main towns they held but French and Malian forces have said there are pockets of Islamist resistance across the north, which is about the size of France.

CAR BOMB

Residents reported a bomb in the east of Kidal on Thursday.

"It was a car bomb that exploded in a garage," said one resident who went to the scene but asked not to be named.

"The driver and another man were killed. Two other people were injured," he added.

A French defense ministry official confirmed there had been a car bomb but said it did not appear that French troops, based at the town's airport, had been targeted.

Earlier this week, a French soldier was killed in heavy fighting north of Kidal, where French and Chadian troops are hunting Islamists in the Adrar des Ifoghas mountains, which border Algeria.

Operations there are further complicated by the presence of separatist Tuareg rebels, whose rebellion triggered the fighting in northern Mali last year but were sidelined by the better-armed Islamists.

Having dispatched its forces to prevent an Islamist advance south in January, Paris is eager not to become bogged down in a long-term conflict in Mali. But their Malian and African allies have urged French troops not to pull out too soon.

(Additional reporting by Emanuel Braun in Gao, Adama Diarra in Bamako, David Lewis and John Irish in Dakar and Adrian Croft in Brussels; Writing by David Lewis; Editing by Jason Webb and Roger Atwood)

Read More..

Josh Brolin Praises Diane Lane Before Split

News of Josh Brolin and Diane Lane's split after eight years of marriage came as a surprise to many in Hollywood, especially since Josh just recently sang the praises of his spouse while ruminating about how to maintain a successful relationship in the Hollywood spotlight during his recent Gangster Squad junket. Watch the video…

Pics: Top 10 Biggest Divorce Payouts

Diane stars in the upcoming summer blockbuster-to-be Man of Steel as Martha Kent, and Brooke shared a laugh with Josh during the junket that she's a "Woman of Steel."

"She's a very strong woman, extremely strong," the 45-year-old star acknowledged before steering the conversation towards how he hadn't yet seen the new trailer from the Superman film, adding that he's "always excited to see" Diane's performances.

Brooke then more directly asked how the couple manages "a successful relationship in Hollywood in the spotlight," and he replied gamely, "Because we're not really in the spotlight. I mean, we are in times like this [junket interview], but, you know, there's one light. We just do our own thing, and we always have. And we're not in L.A. all the time, we're up north a lot of the time where I grew up, so, you know, you just do what you do. You don't play up into the hype so much."

Video: Diane Lane After Husband Josh Brolin's Arrest

Stay tuned to ET for more news on Josh Brolin and Diane Lane's split.

Read More..

Flu shot did poor job against worst bug in seniors

ATLANTA (AP) — For those 65 and older, this season's flu shot is only 9 percent effective against the most common and dangerous flu bug, according to a startling new government report.

Flu vaccine tends to protect younger people better than older ones and never works as well as other kinds of vaccines. But experts say the preliminary results for seniors are disappointing and highlight the need for a better vaccine.

For all age groups, the vaccine's effectiveness is moderate at 56 percent, which is nearly as well as other flu seasons, the Centers for Disease Control and Prevention said Thursday.

For those 65 and older, it is 27 percent effective against the three strains in the vaccine, the lowest in about a decade but not far below from what's expected. But the vaccine did a particularly poor job of protecting older people against the harshest flu strain, which is causing most of the illnesses this year. CDC officials say it's not clear why.

Vaccinations are now recommended for anyone over 6 months, and health officials stress that some vaccine protection is better than none at all. While it's likely that older people who were vaccinated are still getting sick, many of them may be getting less severe symptoms.

"Year in and year out, the vaccine is the best protection we have," said CDC flu expert Dr. Joseph Bresee.

To be sure, the preliminary data for seniors is less than definitive. It is based on fewer than 300 people scattered among five states.

But it will no doubt surprise many people that the effectiveness is that low, said Michael Osterholm, a University of Minnesota infectious disease expert who has tried to draw attention to the need for a more effective flu vaccine.

Among infectious diseases, flu is considered one of the nation's leading killers. On average, about 24,000 Americans die each flu season, according to the CDC.

This flu season started in early December, a month earlier than usual, and peaked by the end of year. Older people are most vulnerable to flu and its complications, and the nation has seen some of the highest hospitalization rates for people 65 and older in a decade.

Flu viruses tend to mutate more quickly than others, and it's not unusual for multiple strains to be spreading at the same time. A new vaccine is formulated each year targeting the three strains expected to be the major threats. But that involves guesswork.

Because of these challenges, scientists tend to set a lower bar for flu vaccine. While childhood vaccines against diseases like measles are expected to be 90 or 95 percent effective, a flu vaccine that's 60 to 70 percent effective in the U.S. is considered pretty good.

By that standard, this year's vaccine is OK. The 56 percent effectiveness figure means people have a 56 percent lower chance of winding up at the doctor for treatment of flu symptoms.

For seniors, a flu vaccine is considered pretty good if it's in the 30 to 40 percent range, said Dr. Arnold Monto, a University of Michigan flu expert.

Older people have weaker immune systems that don't respond as well to flu shots. That's why a high-dose version was recently made available for those 65 and older. The new study was too small to show whether that made a difference this year.

The CDC estimates are based on about 2,700 people who got sick in December and January. The researchers traced back to see who had gotten flu shots and who hadn't. An earlier study put the vaccine's overall effectiveness slightly higher, at 62 percent.

The CDC's Bresee said there's a danger in providing preliminary results because it may result in people doubting — or skipping — flu shots. But the data was released to warn older people who got shots that they may still get sick and shouldn't ignore any serious flu-like symptoms, he said.

The new data highlights an evolution in how experts are evaluating flu vaccine effectiveness. For years, it was believed that if the viruses in the vaccine matched the ones spreading around the country, then the vaccine would be effective. This year's shot was a good match to the bugs going around this winter, including the harsher H3N2 that tends to make people sicker.

But the season proved to be a moderately severe one, with many illnesses occurring in people who'd been vaccinated.

____

Online:

CDC report: http://www.cdc.gov/mmwr

Read More..

Wall Street drops again, data raises growth concerns

NEW YORK (Reuters) - U.S. stocks fell on Thursday and were on track for their biggest two-day decline since November as weak data suggested expectations for economic growth were overly optimistic.

The two-day decline marked the U.S. stock market's first sustained pullback this year. The Standard & Poor's 500 is up 5.2 percent so far this year. The benchmark index has climbed for seven straight weeks, putting it near five-year highs.

In the latest economic data, initial claims for unemployment benefits rose more than expected last week while the Federal Reserve Bank of Philadelphia said its index of business conditions in the U.S. mid-Atlantic region fell in February to minus 12.5, the lowest in eight months.

"The Philly Fed report was troublingly weak, and adds to concerns about whether growth will remain up," said Brad Sorensen, director of market and sector analysis at Charles Schwab in Denver. "The only growth we're seeing is sluggish."

On Wednesday, the S&P 500 and the Nasdaq posted their worst daily declines of the year after the minutes from the Federal Reserve's most recent meeting sparked concerns that the central bank may rein in its economic stimulus measures.

"The upside momentum in markets appears to be coming to an end as we consolidate recent gains," said Adam Sarhan, chief executive at Sarhan Capital in New York. "If the S&P breaks under its 50-day moving average, something more serious could be in store."

The S&P 500 would need to fall 1.9 percent to reach that level of 1,473.58.

Other reports showed consumer prices were flat in January while existing-home sales edged higher and left the inventory of homes at the lowest level in 13 years.

Wal-Mart Stores Inc shares gained 2.5 percent to $70.94 and helped curb the Dow's decline after the world's largest retailer reported earnings that beat expectations, though early February sales were sluggish.

The Dow Jones industrial average <.dji> was down 70.03 points, or 0.50 percent, at 13,857.51. The Standard & Poor's 500 Index <.spx> was down 11.23 points, or 0.74 percent, at 1,500.72. The Nasdaq Composite Index <.ixic> was down 36.50 points, or 1.15 percent, at 3,127.92.

The benchmark S&P 500 index has dropped 1.9 percent over the past two sessions, the biggest two-day decline since November.

Wall Street will soon face another test with the upcoming debate in Washington over the automatic across-the-board spending cuts put in place as part of a larger congressional budget fight. Those cuts, set to kick in on March 1 unless lawmakers agree on an alternative, are expected to depress economic growth.

Semiconductor stocks ranked among the weakest of the day, pressuring the Nasdaq as the Philadelphia Semiconductor index <.sox> fell 1.8 percent. Intel Corp fell 2.2 percent to $20.27 while Advanced Micro Devices lost 4.8 percent to $2.57 as the S&P's biggest percentage decliner.

The semiconductor sector has performed well so far in 2013, rising 8.4 percent.

In company news, shares of supermarket operator Safeway Inc jumped 13.4 percent to $22.83 and ranked as the S&P 500's top percentage gainer after the company reported earnings that beat expectations.

In contrast, shares of VeriFone Systems Inc tumbled nearly 40 percent to $19.28 after the credit-card swipe machine maker forecast first- and second-quarter profits well below expectations.

Of the 427 companies in the S&P 500 that have reported results so far, 69.3 percent have exceeded analysts' expectations, compared with a 62 percent average since 1994 and 65 percent over the past four quarters, according to Thomson Reuters data through Thursday morning.

Fourth-quarter earnings for S&P 500 companies are estimated to have risen 5.9 percent, according to the data, above a 1.9 percent forecast at the start of the earnings season.

Berry Petroleum Co jumped 17.3 percent to $45.25 after oil and gas producer Linn Energy LLC said it would buy the company in an all-stock deal valued at $4.3 billion, including debt. Linn Energy shares advanced 1.9 percent to $37.33.

(Editing by Kenneth Barry and Jan Paschal)

Read More..